Moderna’s COVID-19 vaccine SPIKEVAX receives approval for full registration
Published
Related content
- COVID-19 vaccine: SPIKEVAX (elasomeran)The TGA approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration.
- TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and olderOn 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, SPIKEVAX (elasomeran), for use as a booster dose in individuals aged 12 years and older.
- TGA commences evaluation of Moderna COVID-19 vaccine (SPIKEVAX) for potential transition to full registrationThe TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older.